NasdaqGS:CAPRBiotechs
Has Capricor Therapeutics (CAPR) Run Too Far After Its Multi Year Share Price Surge
Investors may be wondering if Capricor Therapeutics at around US$33.94 is still offering value after a strong run, or if most of the opportunity is already reflected in the price.
The stock has returned 1.1% over the last week, 6.2% over the past month and 19.9% year to date, with a very large 1 year return of 386.9% and around 7x over 3 years. This naturally raises questions about the current balance of risk and reward.
Recent coverage has focused on Capricor Therapeutics because of its...